Abbott Q3 sales rise 14.5% to $13.01 billion amid planned Nutrition spinoff

• Abbott Laboratories (NYSE:ABT) reported third-quarter 2026 revenue of $13.01 billion, up 14.5% year over year and slightly above analysts' $12.99 billion estimate, with comparable sales growth of 7%.
• Adjusted diluted EPS of $1.42 matched Wall Street expectations, while GAAP diluted EPS fell to $0.53 from $0.94 a year earlier.
• Abbott plans to separate its Nutrition business by the end of 2027 and maintained the midpoint of its full-year adjusted EPS forecast, narrowing guidance to $5.50–$5.55.

Abbott Laboratories (NYSE:ABT) reported third-quarter 2026 revenue of $13.01 billion, up 14.5% year over year, slightly exceeding Wall Street's $12.99 billion estimate.

Adjusted diluted earnings reached $1.42 per share, matching consensus estimates, while GAAP diluted EPS declined to $0.53 from $0.94 a year earlier.

Diagnostics revenue increased 46.7% to $3.31 billion, benefiting from the Exact Sciences acquisition, while Medical Devices sales rose 6.9% to $5.83 billion.

Nutrition revenue increased 5.1% to $2.26 billion, while Established Pharmaceuticals generated $1.61 billion, representing reported growth of 6.8%.

Abbott announced plans to separate its Nutrition business into an independent publicly traded company by late 2027, allowing both businesses to pursue distinct strategies.

The company narrowed its full-year adjusted EPS guidance to $5.50–$5.55, projected fourth-quarter adjusted EPS of $1.62–$1.67 and forecast approximately 6% comparable annual sales growth.